Announced
Completed
Financials
Tags
pharmaceutical manufacturing
Private
Majority
Cross Border
Joint Venture
Pharmaceuticals
Friendly
Single Bidder
United Kingdom
Completed
Synopsis
Kyowa Kirin, a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines, and Grunenthal, an independent, family-owned, international research-based pharmaceutical company, formed a joint venture. Financial terms were not disclosed. "The established medicines portfolio has a proud history of delivering life-changing value for patients. Today's announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality," Jeremy Morgan, Kyowa Kirin President.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.